Metis TechBio (RO9) Stock Overview
Engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
RO9 Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Metis TechBio Co., Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | HK$1.74 |
| 52 Week High | HK$2.54 |
| 52 Week Low | HK$1.74 |
| Beta | 0 |
| 1 Month Change | n/a |
| 3 Month Change | n/a |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -29.80% |
Recent News & Updates
Recent updates
Shareholder Returns
| RO9 | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | -18.5% | 0.4% | 3.9% |
| 1Y | n/a | -13.6% | 2.6% |
Return vs Industry: Insufficient data to determine how RO9 performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how RO9 performed against the German Market.
Price Volatility
| RO9 volatility | |
|---|---|
| RO9 Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 8.5% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in DE Market | 12.9% |
| 10% least volatile stocks in DE Market | 2.7% |
Stable Share Price: RO9's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: Insufficient data to determine RO9's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | n/a | Tsai-Ta Lai | www.metistechbio.com |
Metis TechBio Co., Ltd. engages in research and development of AI-empowered nanomaterial for the delivery and application of active agents across carbon-based life forms in Chinese Mainland and United States. It develops NanoForge, a suite of synergistic technologies that includes novo lipid library, AI foundational models, METiSAIAgent, quantum chemistry and molecular dynamics simulations, and AI-driven screening platforms. The company also develops specialized platforms, such as AiTEM, AiLNP and AiRNA that simulate, predict, and interpret nanoscale interactions enabling the design, optimization, and validation of advanced nanomaterials and associated payloads.
Metis TechBio Co., Ltd. Fundamentals Summary
| RO9 fundamental statistics | |
|---|---|
| Market cap | €2.07b |
| Earnings (TTM) | -€49.63m |
| Revenue (TTM) | €13.30m |
Is RO9 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RO9 income statement (TTM) | |
|---|---|
| Revenue | CN¥105.00m |
| Cost of Revenue | CN¥1.91m |
| Gross Profit | CN¥103.09m |
| Other Expenses | CN¥494.92m |
| Earnings | -CN¥391.84m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.34 |
| Gross Margin | 98.18% |
| Net Profit Margin | -373.18% |
| Debt/Equity Ratio | 3.8% |
How did RO9 perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/05/26 22:53 |
| End of Day Share Price | 2026/05/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Metis TechBio Co., Ltd. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.